US 12,269,857 B2
Protein tyrosine-tyrosine analogs and methods of using the same
Daniel Anthony Briere, Morgantown, IN (US); Daniel Christopher Lopes, Zionsville, IN (US); and Avinash Muppidi, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Oct. 11, 2023, as Appl. No. 18/484,451.
Application 18/484,451 is a continuation of application No. 17/494,394, filed on Oct. 5, 2021, granted, now 11,820,803.
Application 17/494,394 is a continuation of application No. 16/665,072, filed on Oct. 28, 2019, granted, now 11,155,592, issued on Oct. 26, 2021.
Claims priority of provisional application 62/793,544, filed on Jan. 17, 2019.
Claims priority of provisional application 62/754,244, filed on Nov. 1, 2018.
Prior Publication US 2024/0209055 A1, Jun. 27, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61P 3/04 (2006.01); C07K 14/575 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 14/57545 (2013.01) [A61P 3/04 (2018.01); A61K 9/0053 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01)] 12 Claims
 
1. A Peptide Tyrosine-Tyrosine (PYY) analog comprising an amino acid sequence of:
(Formula I)
PKPEX7PX9X10DASPEEX17X18RYYX22X23LRHYLNX30LTRQRY, 
wherein X7is any amino acid with a functional group available for conjugation and the functional group is conjugated to a C16-C22 fatty acid,
wherein X9 is E or G,
wherein X10 is E or K,
wherein X17is L or W,
wherein X18 is N or Q,
wherein X22 is A or I,
wherein X23 is E, D or S,
wherein X30 is E or W (SEQ ID NO:3), and
wherein a C-terminal amino acid is optionally amidated.